Cargando…
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
Renal injury almost always accompanies the multisystem organ failure that precedes cardiac transplantation and renal function is further compromised by the nephrotoxicity of calcineurin inhibitors posttransplant. Renal dysfunction in turn causes significant morbidity and mortality. The development o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964935/ https://www.ncbi.nlm.nih.gov/pubmed/32047843 http://dx.doi.org/10.1097/TXD.0000000000000967 |
_version_ | 1783488553849716736 |
---|---|
author | Schenk, Austin D. Anderson, Douglas J. Cole, Robert T. Badell, Idelberto R. Larsen, Christopher P. |
author_facet | Schenk, Austin D. Anderson, Douglas J. Cole, Robert T. Badell, Idelberto R. Larsen, Christopher P. |
author_sort | Schenk, Austin D. |
collection | PubMed |
description | Renal injury almost always accompanies the multisystem organ failure that precedes cardiac transplantation and renal function is further compromised by the nephrotoxicity of calcineurin inhibitors posttransplant. Renal dysfunction in turn causes significant morbidity and mortality. The development of belatacept was motivated by need for an alternative to calcineurin-based immunosuppression, particularly in renal transplantation where the nephrotoxicity of calcineurin inhibitors reduce graft longevity and adverse cardiovascular effects of calcineurin inhibitors increase overall mortality. In 2011, the FDA approved belatacept for use in renal transplantation. Seven-year data from the multicenter randomized phase III BENEFIT trial, which compared belatacept with cyclosporine in renal transplant recipients, show belatacept therapy offers both improved renal function and 43% risk reduction for the combined endpoint of graft loss and death. At present, belatacept use is predominantly confined to renal transplant recipients; however, reports of belatacept use in other transplant settings are emerging. Here, we describe successful long-term use of belatacept in a kidney-after-heart transplant recipient and review use of belatacept in cardiothoracic and other nonrenal transplant settings. |
format | Online Article Text |
id | pubmed-6964935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-69649352020-02-11 De Novo Belatacept in a Kidney-After-Heart Transplant Recipient Schenk, Austin D. Anderson, Douglas J. Cole, Robert T. Badell, Idelberto R. Larsen, Christopher P. Transplant Direct Heart Transplantation Renal injury almost always accompanies the multisystem organ failure that precedes cardiac transplantation and renal function is further compromised by the nephrotoxicity of calcineurin inhibitors posttransplant. Renal dysfunction in turn causes significant morbidity and mortality. The development of belatacept was motivated by need for an alternative to calcineurin-based immunosuppression, particularly in renal transplantation where the nephrotoxicity of calcineurin inhibitors reduce graft longevity and adverse cardiovascular effects of calcineurin inhibitors increase overall mortality. In 2011, the FDA approved belatacept for use in renal transplantation. Seven-year data from the multicenter randomized phase III BENEFIT trial, which compared belatacept with cyclosporine in renal transplant recipients, show belatacept therapy offers both improved renal function and 43% risk reduction for the combined endpoint of graft loss and death. At present, belatacept use is predominantly confined to renal transplant recipients; however, reports of belatacept use in other transplant settings are emerging. Here, we describe successful long-term use of belatacept in a kidney-after-heart transplant recipient and review use of belatacept in cardiothoracic and other nonrenal transplant settings. Wolters Kluwer Health 2019-12-24 /pmc/articles/PMC6964935/ /pubmed/32047843 http://dx.doi.org/10.1097/TXD.0000000000000967 Text en Copyright © 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Heart Transplantation Schenk, Austin D. Anderson, Douglas J. Cole, Robert T. Badell, Idelberto R. Larsen, Christopher P. De Novo Belatacept in a Kidney-After-Heart Transplant Recipient |
title | De Novo Belatacept in a Kidney-After-Heart Transplant Recipient |
title_full | De Novo Belatacept in a Kidney-After-Heart Transplant Recipient |
title_fullStr | De Novo Belatacept in a Kidney-After-Heart Transplant Recipient |
title_full_unstemmed | De Novo Belatacept in a Kidney-After-Heart Transplant Recipient |
title_short | De Novo Belatacept in a Kidney-After-Heart Transplant Recipient |
title_sort | de novo belatacept in a kidney-after-heart transplant recipient |
topic | Heart Transplantation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964935/ https://www.ncbi.nlm.nih.gov/pubmed/32047843 http://dx.doi.org/10.1097/TXD.0000000000000967 |
work_keys_str_mv | AT schenkaustind denovobelataceptinakidneyafterhearttransplantrecipient AT andersondouglasj denovobelataceptinakidneyafterhearttransplantrecipient AT colerobertt denovobelataceptinakidneyafterhearttransplantrecipient AT badellidelbertor denovobelataceptinakidneyafterhearttransplantrecipient AT larsenchristopherp denovobelataceptinakidneyafterhearttransplantrecipient |